TORONTO, Oct. 25, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce it has now received $7.27 Million in gross cash proceeds from the settlement agreement announced on October 2, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial agreement dispute. Additional consideration includes products and services described below.
Read more at newswire.caMediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to Cash
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
